Stifel Financial Corp Athira Pharma, Inc. Transaction History

Stifel Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $20,734 - $31,541	-8,786 Reduced 26.16%	24,800 $73,000
Q1 2023 May 12, 2023	SELL	$2.26 - $4.22 $992 - $1,852	-439 Reduced 1.29%	33,586 $83,000
Q4 2022 Feb 13, 2023	BUY	$2.76 - $3.71 $65,757 - $88,390	23,825 Added 233.58%	34,025 $107,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $29,886 - $40,392	10,200 New	10,200 $30,000
Q1 2021 May 14, 2021	SELL	$16.9 - $29.77 $428,938 - $755,592	-25,381 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.48 - $34.3 $418,278 - $870,568	25,381 New	25,381 $869,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.